CVKD שווי כולל של נכסי החברה Cadrenal Therapeutics Inc.

Cadrenal Therapeutics (CVKD) is conducting tests on a new anticoagulant while maintaining financial stability for future research stages. The market trend for the company's total assets is 5.78. The business relies on partnerships with cardiac centers to develop therapy for renal failure. Additionally, Cadrenal Therapeutics (CVKD) utilizes external contractors for drug manufacturing, conducting trials, and implementing logistical schemes to promote its products.

Total assets represent the aggregate of a company's resources and obligations, reverse-calculated via return on assets (ROA) to determine the company's actual fundamental basis. The dynamics of total assets allow for an assessment of Cadrenal Therapeutics (CVKD) and its ability to fund the development of safe antithrombotic drugs for patients with renal failure, distinguishing temporary market undervaluation from systemic business decline.